Rituximab (RTX) has become a standard therapy for certain B cell malignancies and autoimmune diseases. We report 2 RTX-treated patients who developed severe tick-borne encephalitis virus (TBEV) infection. The inability to generate new antibody responses renders RTX-treated patients susceptible to TBEV, impedes laboratory diagnosis, and necessitates preventive vaccination in endemic areas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903409 | PMC |
| http://dx.doi.org/10.1093/ofid/ofx204 | DOI Listing |
Publication Analysis
Top Keywords
severe tick-borne
8
tick-borne encephalitis
8
rtx-treated patients
8
cases severe
4
encephalitis rituximab-treated
4
rituximab-treated patients
4
patients germany
4
germany implications
4
implications diagnosis
4
diagnosis prevention
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!